Pfizer Inc. (PFE) Is Gaining Attention: Key Information to Consider Before Investing

Pfizer: Recent Trends and Key Insights

Pfizer (PFE) has recently attracted significant attention among investors. If you're considering this stock, it's important to examine several factors that could influence its short-term performance.

Over the past month, Pfizer's share price has edged up by 0.5%, slightly trailing the Zacks S&P 500 composite's 0.6% gain. Meanwhile, the Zacks Large Cap Pharmaceuticals sector, which includes Pfizer, declined by 0.9% during the same period. The main question now is: What direction might Pfizer's stock take in the near future?

While news headlines and speculation can cause quick price swings, long-term investment decisions are typically driven by fundamental data.

Earnings Forecast Adjustments

At Zacks, changes in projected earnings are a primary focus, as the present value of expected future earnings is a key factor in determining a stock's fair value.

We monitor how analysts update their earnings forecasts based on the latest business developments. When these estimates rise, the stock's fair value usually increases, which can attract more buyers and push the price higher. Research consistently shows a strong link between earnings estimate revisions and short-term stock price movements.

Currently, Pfizer is anticipated to report earnings of $0.77 per share for this quarter, a decrease of 16.3% compared to the previous year. Over the past month, the Zacks Consensus Estimate for this figure has increased by 4%.

For the full fiscal year, the consensus estimate stands at $2.97 per share, reflecting a 7.8% year-over-year decline, with a slight 0.1% increase in the last 30 days.

Looking ahead to the next fiscal year, analysts expect earnings of $2.82 per share, which is 5.1% lower than the current year's projection. This estimate has decreased by 0.7% in the past month.

The Zacks Rank, a proprietary rating system with a proven track record, incorporates earnings estimate changes and other factors to provide a clearer outlook on a stock's potential. Given the recent shifts in consensus estimates and related metrics, Pfizer currently holds a Zacks Rank #3 (Hold).

The chart below illustrates the trend in Pfizer's forward 12-month consensus EPS estimate:

Revenue Outlook

While earnings growth is a strong indicator of financial health, sustained revenue growth is essential for long-term profitability. Without increasing sales, it's difficult for a company to boost earnings over time.

For the current quarter, Pfizer's consensus sales estimate is $13.83 billion, up 0.9% from a year ago. For the current and next fiscal years, projected revenues are $61 billion and $58.84 billion, representing declines of 2.5% and 3.5%, respectively.

Recent Performance and Earnings Surprises

In its most recent quarter, Pfizer reported revenues of $17.56 billion, a 1.2% decrease from the previous year. Earnings per share came in at $0.66, compared to $0.63 a year earlier.

These results exceeded the Zacks Consensus Estimate of $16.84 billion in revenue by 4.26%, and the EPS beat expectations by 15.79%.

Pfizer has surpassed consensus EPS estimates in each of the last four quarters and outperformed revenue estimates three times during this period.

Valuation Analysis

Assessing a stock's valuation is crucial for making informed investment choices. Comparing current valuation metrics—such as price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF)—to historical averages and industry peers helps determine whether a stock is undervalued, fairly valued, or overvalued.

The Zacks Value Style Score, which rates stocks from A to F based on a range of valuation measures, is a useful tool for this analysis. Pfizer currently receives an A grade, indicating it is trading at a discount relative to its peers.

Summary

The information presented here, along with additional resources on Zacks.com, can help you decide whether to pay attention to the current market buzz around Pfizer. Based on its Zacks Rank #3, the stock is expected to perform in line with the broader market in the near term.

Top Stock Picks from Zacks

The Zacks research team has identified five stocks with the potential to double in value in the coming months. Among these, Director of Research Sheraz Mian highlights one standout pick—a lesser-known satellite communications company poised for rapid growth as the space industry expands. Analysts anticipate a significant revenue surge in 2025. While not all top picks achieve such gains, this company could outperform previous winners like Hims & Hers Health, which soared over 200%.